Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.36 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29833956 | 1.00 | PDE5A (0.48) | PDE5AAPPJAK2KDRFLT1 | |
| SCHEMBL20119986 | 0.85 | APP (0.42) | PDE5AAPPJAK2PDE2AHDAC6 | |
| SCHEMBL20119919 | 0.84 | PKM (0.50) | PDE5AAPPPDE10APOLB | |
| SCHEMBL20119853 | 0.83 | JAK2 (0.46) | PDE5AAPPJAK2KDRFLT1 | |
| SCHEMBL20119756 | 0.82 | KCNH3 (0.44) | PDE5AAPPPDE2AHDAC6TTBK1 | |
| SCHEMBL20119894 | 0.82 | CYP1A2 (0.42) | PDE5AAPPPDE2AROCK2TMIGD3 | |
| SCHEMBL20119599 | 0.81 | PDE2A (0.41) | PDE5AAPPJAK2PDE2A | |
| SCHEMBL20119640 | 0.81 | KCNH3 (0.40) | PDE5AAPPJAK2KDRFLT1 | |
| SCHEMBL20119651 | 0.81 | APP (0.44) | PDE5AAPPPDE2AHDAC6TTBK1 | |
| SCHEMBL20119652 | 0.80 | HDAC6 (0.51) | PDE5AAPPPDE2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047208-A1 | RNA Splicing Modulation | THE GENERAL HOSPITAL CORPORATION | 2023-02-16 | — | — | US | claimed |
| WO-2021138678-A1 | RNA SPLICING MODULATION | THE GENERAL HOSPITAL CORPORATION (US) | 2021-07-08 | — | — | WO | claimed |
| US-20240382491-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20240041886-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230047208-A1 | RNA Splicing Modulation | THE GENERAL HOSPITAL CORPORATION | 2023-02-16 | — | — | US | disclosed |
| US-20230047208-A1 | RNA Splicing Modulation | THE GENERAL HOSPITAL CORPORATION | 2023-02-16 | — | — | US | disclosed |
| EP-4084796-A1 | RNA SPLICING MODULATION | The General Hospital Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2021138678-A1 | RNA SPLICING MODULATION | THE GENERAL HOSPITAL CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138678-A1 | RNA SPLICING MODULATION | THE GENERAL HOSPITAL CORPORATION (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE5A 3202/4885APP 604/4885JAK2 4665/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | PDE5A 3202/4885APP 604/4885JAK2 4665/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE5A 3202/4885APP 604/4885JAK2 4665/4885 |
| US-20240382491-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | PDE5A 2872/4885APP 45/4885JAK2 4238/4885 |
| US-20240041886-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | PDE5A 280/4885APP 2552/4885JAK2 1172/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | PDE5A 3202/4885APP 604/4885JAK2 4665/4885 |
| US-20230047208-A1 | RNA Splicing Modulation | RBM17, NSUN2, HNRNPUL2 | PDE5A 3952/4885APP 2608/4885JAK2 4511/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | PDE5A 3202/4885APP 604/4885JAK2 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.